A cancer-specific L-type amino acid transporter 1 (LAT1) is highly expressed in cancer tissues.

Inhibiting the function of LAT1 has been known to have anti-tumour effects, but there has been limited progress in the development of radionuclide therapy agents targeting LAT1.

Now, a multidisciplinary research team at Osaka University has established a targeted alpha-therapy with a novel drug targeting LAT1.

The research was published in the journal Cancer Science. 

The researchers first produced the alpha-ray emitter ²¹¹Astatine, no easy task given that Astatine (At) is the rarest naturally occurring element on Earth.

Targeted alpha-therapy selectively delivers α-emitters to tumours; the advantage over conventional β-therapy is that alpha decay is highly targeted and the high linear energy transfer causes double-strand breaks to DNA, effectively causing cell death.

The short half-life and limited tissue penetration of alpha radiation ensures high therapeutic effects with few side-effects to surrounding normal cells.

Next, to carry the radioisotope into cancer cells, the researchers attached it to α-Methyl-L-tyrosine, which has high affinity for LAT1.

This subterfuge exploits the elevated nutrient requirements of rapidly multiplying cancer cells.

"We found that ²¹¹At-labeled α-methyl-L-tyrosine (²¹¹At-AAMT) had high affinity for LAT1, inhibited tumour cells, and caused DNA double-strand breaks in vitro," reports Associate Professor Kazuko Kaneda-Nakashima, lead author. "Extending our research, we assessed the accumulation of 211At-AAMT and the role of LAT1 in an experimental mouse model. Further investigations on a human pancreatic cancer cell line showed that 211At-AAMT selectively accumulated in tumours and suppressed growth. At a higher dose, it even inhibited metastasis in the lung of a metastatic melanoma mouse model."

Professor Atsushi Shinohara, senior author, explains, "We could establish the efficacy of ²¹¹Astatine in the treatment of cancer including advanced and metastatic malignancies, as well as the utility of the amino acid transporter LAT1 as a vehicle for radionuclide therapy. As the drug is delivered cancer-specifically it can attack from inside the cell after being taken in as a nutrient."

Adding to efficacy is dosing convenience.

As an injectable short-range radiopharmaceutical, ²¹¹At-AAMT may be administered in outpatient clinics, a huge advantage over conventional radiation protocols, and may even be an alternative to surgery in specific cancers.

This approach has immense potential to revolutionise radionuclide therapy of not only pancreatic cancer but other malignancies that lack effective treatment including advanced or metastatic disease.

Source: Osaka University